Iron Chelation Therapy Targeting the Labile Iron Pool
🧪 Overview
Lipophilic iron chelators (deferasirox, VK28 analogs) cross the BBB to sequester labile iron, preventing Fenton chemistry and subsequent lipid peroxidation in astrocytes. This preserves AQP4 perivascular localization and water homeostasis. Mechanistically plausible given iron-dependent ferroptosis, but prior clinical trials of deferoxamine in TBI and stroke showed limited efficacy, raising concerns about relevance to human acute CNS injury. Requires rigorous dose-response with MRI-based iron quantification and brain drug levels.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["CSF Arterial Inflow<br/>Periarterial Space"]
B["AQP4 on Astrocyte Endfeet<br/>Perivascular Polarization"]
C["Glymphatic Flow<br/>ISF Convective Clearance"]
D["Abeta/Tau Efflux<br/>Perivenous Drainage"]
E["Lymphatic Outflow<br/>Cervical Lymph Nodes"]
F["AQP4 Mislocalization<br/>in AD/Aging"]
G["Reduced ISF Clearance<br/>Aggregate Accumulation"]
A --> B
B --> C
C --> D
D --> E
F -.->|"impairs"| C
F --> G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#1b5e20,stroke:#81c784,color:#81c784
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — LABILE
No curated PDB or AlphaFold mapping for LABILE yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for Labile iron pool (LIP).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF patients with acute ischemic stroke (NIHSS 6-15) receive deferasirox (20 mg/kg/day IV for 5 days starting within 6 hours of symptom onset) THEN brain R2* relaxometry in the ischemic territory will | R2* reduction ≥25% indicating decreased brain iron in the lesioned hemisphere | — no observation — | pending | 0.45 |
| IF C57BL/6 mice receive VK28 analog (10 mg/kg IP daily for 14 days) starting 1 hour after middle cerebral artery occlusion (MCAO), THEN quantitative immunofluorescence of AQP4 perivascular coverage wi | AQP4 perivascular localization restored to ≥70% of sham control; blood-brain barrier permeability reduced by ≥40% | — no observation — | pending | 0.55 |
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |